University of Defense, Hradec Králové, Czech Republic.
Eur J Pediatr. 2009 Sep;168(9):1031-5. doi: 10.1007/s00431-009-0972-6. Epub 2009 Mar 20.
Vaccines against human papillomavirus (HPV), the primary causative agent in cervical cancer, are licensed. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on the introduction of HPV vaccines in central Europe. Eight countries currently have medical representatives on CEVAG: the Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Slovakia and Turkey. By raising awareness and disseminating information, CEVAG aims to promote the efficient and safe use of vaccines to prevent, control and if possible eliminate infectious diseases. In January 2008, the European Centre for Disease Prevention and Control published a report entitled Guidance for the Introduction of HPV Vaccines in EU Countries. Members of CEVAG have taken the information relevant to their countries from this report and, with consideration of local issues, produced these guidance recommendations for the introduction of HPV vaccines in the CEVAG region, which may be adapted for use in individual countries.
针对宫颈癌的主要致病原人乳头瘤病毒（HPV）的疫苗已经获得许可。本文载有中欧疫苗咨询小组（CEVAG）关于在中欧引入 HPV 疫苗的指导意见声明。目前，CEVAG 有八个国家的医学代表：捷克共和国、爱沙尼亚、匈牙利、立陶宛、波兰、罗马尼亚、斯洛伐克和土耳其。CEVAG 通过提高认识和传播信息，旨在促进疫苗的有效和安全使用，以预防、控制和在可能的情况下消除传染病。2008 年 1 月，欧洲疾病预防控制中心发布了一份题为《欧盟国家引入 HPV 疫苗指南》的报告。CEVAG 的成员从该报告中获取了与其国家相关的信息，并考虑到当地问题，为 CEVAG 地区引入 HPV 疫苗制定了这些指导建议，这些建议可适用于个别国家。
